logo
J.B. Hunt Recognizes 54 Drivers for Million Mile Safety Accomplishments

J.B. Hunt Recognizes 54 Drivers for Million Mile Safety Accomplishments

Business Wire30-04-2025

LOWELL, Ark.--(BUSINESS WIRE)--J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT), one of the largest supply chain solutions providers in North America, recognized 54 company drivers this week for achieving two, three and four million miles driven without a preventable accident during its annual Million Mile Celebration at company headquarters in Lowell.
Each year, J.B. Hunt hosts the new class of Million Mile drivers and their families at corporate headquarters for a multi-day celebration featuring an awards ceremony with live entertainment, engaging discussions with company leadership, and the Million Mile Walk of Fame, a 24-year annual tradition.
'When we talk about the best of the best, we're talking about the people here this week,' said Nick Hobbs, chief operating officer for J.B. Hunt, during the company's Million Mile Walk of Fame. 'Last year we surpassed our own company safety record set in 2023 for reducing DOT preventable accidents. These drivers are essential for that progress by the example they set and the knowledge and training they share. This is their Million Mile moment, and I'm proud, humbled and honored that they choose to drive with J.B. Hunt.'
This year's Million Mile drivers and their families, led by an emphatic entrance from the Bentonville West High School marching band, made their way along a 300-foot red carpet that spanned two buildings. They were first greeted by the company's executive leadership team, who thanked each for their long-term commitment to safety excellence and expressed how grateful they are to have them as part of the J.B. Hunt family. The remainder of the Walk of Fame featured cheers and high-fives from thousands of company employees, customers, investors and guests who lined the red carpet to celebrate.
With this year's class, J.B. Hunt surpassed 5,000 company drivers to achieve at least one million safe miles. This year's group also included five drivers who achieved four million safe miles, an accomplishment that only elite drivers have achieved. All Million Mile drivers' names are etched into the Million Mile Wall at corporate headquarters. On average, it takes a driver approximately 7-10 years to achieve one million safe miles.
J.B. Hunt's Million Mile event is an important part of the company's culture, reflecting its values of excellence, safety, and integrity. The company prioritizes safety as essential for delivering value and operational excellence for its customers. It continually looks for ways to improve safety measures, including adopting new safety technologies like inward facing cameras and the latest advancements in collision mitigation systems. Company drivers receive safety training that starts during the onboarding process and continues throughout their careers. Million Mile drivers represent the company's long-standing safety culture embraced and enabled by its people.
About J.B. Hunt
J.B. Hunt's vision is to create the most efficient transportation network in North America. The company's industry-leading solutions and mode-neutral approach generate value for customers by eliminating waste, reducing costs and enhancing supply chain visibility. Powered by one of the largest company-owned fleets in the country and third-party capacity through its J.B. Hunt 360°® digital freight marketplace, J.B. Hunt can meet the unique shipping needs of any business, from first mile to final delivery, and every shipment in-between. Through disciplined investments in its people, technology and capacity, J.B. Hunt is delivering exceptional value and service that enable long-term growth for the company and its stakeholders.
J.B. Hunt Transport Services Inc. is a Fortune 500 company, an S&P 500 company and a component of the Dow Jones Transportation Average. Its stock trades on NASDAQ under the ticker symbol JBHT. J.B. Hunt Transport Inc. is a wholly owned subsidiary of JBHT. The company's services include intermodal, dedicated, refrigerated, truckload, less-than-truckload, flatbed, single source, last mile, transload and more. For more information, visit www.jbhunt.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

June 14: Oxbow Fire Department Classic Car Show
June 14: Oxbow Fire Department Classic Car Show

Yahoo

time25 minutes ago

  • Yahoo

June 14: Oxbow Fire Department Classic Car Show

Oxbow Fire Department 9th Annual & Dave Benson 3rd Annual Classic Car Show will be held on Saturday, June 14, from 11 a.m. to 3 p.m. at Oxbow Park on Main Street No fee for cars, 'If it is old or different, bring it down! We will be proud to show it!' Awards will be given for different categories of cars and tractors. There will also be live music. Food, including hot dogs, hamburgers and sausages, will be sold and chicken BBQ will start being served at noon. All proceeds benefit the Oxbow Fire Department. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Homewi$e: How student loans affect homeowners, potential buyers?
Homewi$e: How student loans affect homeowners, potential buyers?

Yahoo

time25 minutes ago

  • Yahoo

Homewi$e: How student loans affect homeowners, potential buyers?

DES MOINES, Iowa — On this week's episode of Homewi$e Amanda Krenz and mortgage expert Tyler Osby discuss how student loan repayment can affect potential homebuyers and current homeowners. Past Episodes: Homewi$e: How student loans affect homeowners, potential buyers? Homewi$e: What you need to know about closing on a home Homewi$e: Who pays the realtors? Homewi$e: Credit check can trigger series of events, what to know Homewi$e: What is a gift of equity, what can it do for you? Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

timean hour ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store